Cara Therapeutics: Scratching At Multiple Indications In 2020 (NASDAQ:CARA) | Seeking Alpha
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Cara Therapeutics - Invest In Weed
κ-opioid receptor - Wikipedia
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
1Washington University, St. Louis, MO, USA; 2Trevi Therapeutics, New Haven, CT, USA; 3University of Miami, Miami, FL, USA Introd
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Articles with Cara Therapeutics, Inc. | page 5
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Cara Therapeutics: Developing Novel Peripheral Kappa Opioid Product Candidates
A New Path to Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)Friday, March 17, 201712:30 PM – 1:30 PMGrand Caribbean Ballroom 7Loews Sapphire Falls ResortOrlando, Florida Survey
CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing? | Semantic Scholar
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - ScienceDirect
